tiprankstipranks
Blurbs

Centessa Pharmaceuticals (CNTA) Gets a Hold Rating from Goldman Sachs

In a report released today, Andrea Tan from Goldman Sachs maintained a Hold rating on Centessa Pharmaceuticals (CNTAResearch Report), with a price target of $8.00. The company’s shares closed last Monday at $4.49, close to its 52-week low of $4.40.

According to TipRanks.com, Tan ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -34.5% and a 0.0% success rate. Tan covers the Healthcare sector, focusing on stocks such as Kodiak Sciences, Vor Biopharma, and Insmed.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Centessa Pharmaceuticals with a $22.50 average price target.

See today’s best-performing stocks on TipRanks >>

Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CNTA in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Centessa Pharmaceuticals PLC is a pharmaceutical company. Its portfolio consists of preclinical to phase 3 uncorrelated programs spanning diseases with high unmet need across oncology, hematology, immunology, inflammation, neuroscience, and rare diseases. Some of its products include Vasopressin V2 Receptor Inhibitor (Lixivaptan), BMP9 Engineered Variant (MGX292), OX2R Agonist (Oral) among others.

Read More on CNTA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed